Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Retz

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Der Urologe. Ausg. A|September 27, 2003
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]J Lehmann, M Retz, G Steiner, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Der Urologe. Ausg. A|September 27, 2003
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]J Lehmann, M Retz, G Steiner, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 9